ANI Pharmaceuticals（ANIP）株式概要
バイオ医薬品会社であるANIファーマシューティカルズ・インクは、米国内外でブランド医薬品およびジェネリック医薬品の開発、製造、販売を行っている。 詳細
ANIP Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ANI Pharmaceuticals, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$86.03 |
| 52週高値 | US$99.50 |
| 52週安値 | US$62.61 |
| ベータ | 0.43 |
| 1ヶ月の変化 | 6.07% |
| 3ヶ月変化 | 11.44% |
| 1年変化 | 31.79% |
| 3年間の変化 | 65.35% |
| 5年間の変化 | 158.04% |
| IPOからの変化 | 1,265.56% |
最新ニュース
ナラティブの更新 • Jul 01
ANIP: Higher Long Run Margins Will Support Bullish Case Ahead
Analysts have raised their price target for ANI Pharmaceuticals from $90.00 to $100.00, citing updated assumptions related to revenue growth, profit margins, and a slightly higher future P/E multiple. What’s in the News for ANI Pharmaceuticals ANI Pharmaceuticals announced a voluntary, firm initiated Class II recall of Estradiol Gel 0.1% packets after some containers were found empty or partially full, covering 3,964 cartons from Lot M251109, with distribution nationwide in the USA, according to a US Food and Drug Administration enforcement report.Seeking Alpha • Jun 26
ANI Pharmaceuticals: Rare Disease Growth At A Generics Multiple
Summary ANI Pharmaceuticals is rated a speculative buy, with the investment thesis centered on Cortrophin Gel's rare disease revenue growth and transformation. Management guides to $540M-$575M Cortrophin revenue in 2026, making rare disease close to 60% of total revenue and supporting a re-rating. A $108 fair value is based on 9x 2026 adjusted EBITDA, offering ~30% upside if Cortrophin growth and gout expansion materialize as guided. Key risks include payer dynamics, Cortrophin concentration, and execution of the gout expansion, with current low multiples justified only if growth falters. Read the full article on Seeking Alpha分析記事 • Jun 21
ANI Pharmaceuticals (ANIP) Stock Could Be 29.5% Below Fair Value After Recent Pullback
ANI Pharmaceuticals (ANIP) has drawn investor interest after recent share price moves, with the stock closing at US$79.49 and showing mixed short term performance alongside longer term total returns. See our latest analysis for ANI Pharmaceuticals. The recent dip in ANI Pharmaceuticals’ share price, including a 1-month share price return of 3.9% down from its recent high, contrasts with a 1-year total shareholder return of 21.25%. This suggests longer term momentum has still been positive...
ナラティブの更新 • Jun 17
ANIP: Buyback And Stronger Cash Generation Will Support Future Earnings Power
The analyst price target for ANI Pharmaceuticals has been adjusted from $109.88 to $112.71. Analysts attribute the change to updated fair value estimates and a slightly higher assumed future P/E multiple as key drivers.Recent updates
ナラティブの更新 • Jul 01
ANIP: Higher Long Run Margins Will Support Bullish Case Ahead
Analysts have raised their price target for ANI Pharmaceuticals from $90.00 to $100.00, citing updated assumptions related to revenue growth, profit margins, and a slightly higher future P/E multiple. What’s in the News for ANI Pharmaceuticals ANI Pharmaceuticals announced a voluntary, firm initiated Class II recall of Estradiol Gel 0.1% packets after some containers were found empty or partially full, covering 3,964 cartons from Lot M251109, with distribution nationwide in the USA, according to a US Food and Drug Administration enforcement report.Seeking Alpha • Jun 26
ANI Pharmaceuticals: Rare Disease Growth At A Generics Multiple
Summary ANI Pharmaceuticals is rated a speculative buy, with the investment thesis centered on Cortrophin Gel's rare disease revenue growth and transformation. Management guides to $540M-$575M Cortrophin revenue in 2026, making rare disease close to 60% of total revenue and supporting a re-rating. A $108 fair value is based on 9x 2026 adjusted EBITDA, offering ~30% upside if Cortrophin growth and gout expansion materialize as guided. Key risks include payer dynamics, Cortrophin concentration, and execution of the gout expansion, with current low multiples justified only if growth falters. Read the full article on Seeking Alpha分析記事 • Jun 21
ANI Pharmaceuticals (ANIP) Stock Could Be 29.5% Below Fair Value After Recent Pullback
ANI Pharmaceuticals (ANIP) has drawn investor interest after recent share price moves, with the stock closing at US$79.49 and showing mixed short term performance alongside longer term total returns. See our latest analysis for ANI Pharmaceuticals. The recent dip in ANI Pharmaceuticals’ share price, including a 1-month share price return of 3.9% down from its recent high, contrasts with a 1-year total shareholder return of 21.25%. This suggests longer term momentum has still been positive...ナラティブの更新 • Jun 17
ANIP: Buyback And Stronger Cash Generation Will Support Future Earnings Power
The analyst price target for ANI Pharmaceuticals has been adjusted from $109.88 to $112.71. Analysts attribute the change to updated fair value estimates and a slightly higher assumed future P/E multiple as key drivers.ナラティブの更新 • Jun 02
ANIP: Raised 2026 Outlook And Buyback Will Support Stronger Earnings Power
Analysts have trimmed their price target on ANI Pharmaceuticals by $0.75 to $109.88, reflecting updated views on fair value, a slightly higher discount rate, moderated revenue growth assumptions, a higher projected profit margin, and a lower future P/E multiple. What's in the News Q1 2026 results: Total net revenues of US$237.5 million, up 20.5% year over year, with Rare Disease products such as Cortrophin Gel and ILUVIEN as key contributors.ナラティブの更新 • May 13
ANIP: Higher Margin Outlook Will Support Bullish Case Over Coming Years
Analysts have maintained their $90.00 price target on ANI Pharmaceuticals, citing updated assumptions around slightly different revenue growth, a higher profit margin, and a lower future P/E as the main factors supporting the unchanged view. What's in the News Raised full year 2026 revenue guidance to a range of US$1.08b to US$1.14b, compared with prior guidance of US$1.055b to US$1.115b (company guidance).ナラティブの更新 • Apr 24
ANIP: 2026 Revenue Guidance And New Launches Will Support Upside Potential
Analysts have kept their $90.00 price target for ANI Pharmaceuticals unchanged, citing relatively steady assumptions for revenue growth, profit margins, and future P/E as the basis for this view. What's in the News Launched Pimozide Tablets 1 mg and 2 mg, a generic version of Orap, with U.S. annual sales for the category of about US$3.1 million based on February 2026 IQVIA data (Key Developments).ナラティブの更新 • Apr 08
ANIP: 2026 Revenue Guidance Will Test Confidence In Margin Assumptions
Analysts lifted their price target on ANI Pharmaceuticals by $9, reflecting updated expectations around revenue growth, profit margin, and future P/E assumptions highlighted in recent Street research. Analyst Commentary While the updated target reflects renewed confidence in revenue and margin assumptions, bearish analysts are still flagging several areas where expectations may be running ahead of what the company can reasonably deliver.ナラティブの更新 • Mar 25
ANIP: Higher 2026 Guidance And Margin Outlook Will Support Stronger Earnings Power
Analysts have raised their price target on ANI Pharmaceuticals by $9 to $110.63, citing updated expectations for revenue growth, profit margins, and a lower future P/E assumption. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as better aligned with updated expectations for revenue and margin performance, which they factor into their cash flow and earnings models.ナラティブの更新 • Mar 11
ANIP: Higher 2026 Guidance Will Test Assumed Margin Expansion
Analysts have lifted their price target on ANI Pharmaceuticals by $9, citing updated assumptions for revenue growth, profit margins, and a revised future P/E multiple that together reshape their view of the stock's long term earnings power. Analyst Commentary While the higher price target reflects updated assumptions, bearish analysts are also flagging several risks that could limit upside if execution or market conditions do not line up with those assumptions.ナラティブの更新 • Feb 24
ANIP: Higher 2026 Revenue Guidance Will Support Richer Forward P/E Multiple
Analysts have lifted their price target on ANI Pharmaceuticals by $9, reflecting updated assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Bullish Takeaways Bullish analysts view the US$9 price target increase as a sign that updated revenue assumptions support a higher valuation multiple on forward earnings.ナラティブの更新 • Feb 10
ANIP: Higher 2026 Revenue Outlook And Refined P/E Framework Will Support Upside
Analysts have raised their price target on ANI Pharmaceuticals by about $1 to $110.50, citing updated views on revenue growth, profit margins, discount rate, and future P/E assumptions reflected in recent research. Analyst Commentary Bullish Takeaways Bullish analysts see the higher US$110.50 target as better aligned with updated assumptions on revenue and margins, suggesting the stock now reflects their latest fundamental work more closely.ナラティブの更新 • Jan 26
ANIP: Future Outlook Will Balance Higher Guidance Expectations And Execution Risks
Analysts have raised their price target on ANI Pharmaceuticals by $9, citing updated expectations for revenue growth, profit margins, and a slightly lower future P/E as key drivers of their revised view. Analyst Commentary While the higher price target signals some confidence around updated revenue and margin expectations, bearish analysts are still flagging areas where the risk and reward profile may feel less attractive for new money.ナラティブの更新 • Jan 12
ANIP: Raised Revenue Outlook And Pipeline Update Will Support Further Upside
Narrative Update on ANI Pharmaceuticals Analysts have trimmed their price target on ANI Pharmaceuticals to about $109.25 from roughly $109.88, citing updated assumptions around slightly higher revenue growth expectations, a modestly lower profit margin outlook, and a small adjustment in the forward P/E multiple. What’s in the News ANI Pharmaceuticals raised its full year 2025 net revenue guidance to a range of US$854 million to US$873 million, compared with prior guidance of US$818 million to US$843 million (Key Developments).ナラティブの更新 • Dec 26
ANIP: Future Outlook Will Balance Corticotropin Momentum And Concentration Risks
Analysts have raised their price target on ANI Pharmaceuticals to $90 from $77, citing continued momentum from Cortrophin Gel, record Q2 sales of $82M, and a 20% full year guidance increase that supports expectations for sustained growth. Analyst Commentary Bearish analysts acknowledge that the higher $90 price target reflects recent strength, but they emphasize that the rating remains at Hold, signaling caution around near term upside.ナラティブの更新 • Dec 12
ANIP: Future Outlook Balances Corticotropin Market Expansion And Competitive Uncertainties
Analysts have lifted their fair value estimate for ANI Pharmaceuticals to $90 from $77 per share as they factor in stronger than expected Cortrophin Gel momentum, higher sales visibility, and an expanding addressable market, despite slightly more conservative growth and margin assumptions. Analyst Commentary Recent Street research reflects a growing divide between optimistic expectations for Cortrophin Gel and a more cautious stance from bearish analysts who question the durability of current momentum and the stock's valuation profile.ナラティブの更新 • Nov 26
ANIP: Continued Momentum Will Drive Upside as Market Opportunities Expand
Analysts have raised their price targets for ANI Pharmaceuticals, with increases ranging from $13 to $28 per share. They cite strong Cortrophin Gel sales momentum, expanded market opportunities, and resilient fundamentals as key factors driving the company’s continued growth outlook.ナラティブの更新 • Nov 10
ANIP: Sustained Revenue Expansion Will Drive Momentum Amid Increasing Market Opportunities
Analysts have increased their average price target for ANI Pharmaceuticals from $105 to approximately $109.88, citing robust Cortrophin Gel performance, expanded market opportunities, and a strengthened revenue outlook. Analyst Commentary Industry analysts are closely monitoring ANI Pharmaceuticals following a series of price target increases.ナラティブの更新 • Sep 25
Expanding ACTH Potential And Rare Disease Markets Will Evolve
ANI Pharmaceuticals’ price target was raised to $105.00 as analysts cite robust Cortrophin Gel prescription trends, a significantly expanded addressable market, and outstanding Q2 revenue growth. Analyst Commentary Bullish analysts highlight that Cortrophin Gel prescription data is consistently surpassing forecasts, indicating stronger-than-expected demand.ナラティブの更新 • Aug 10
Expanding ACTH Potential And Rare Disease Markets Will Evolve
Despite a meaningful reduction in consensus revenue growth forecasts, ANI Pharmaceuticals’ future P/E multiple has declined, improving perceived value and contributing to an upward revision of the consensus analyst price target from $81.38 to $85.75. What's in the News ANI Pharmaceuticals raised 2025 earnings guidance to $818–$843 million from prior $768–$793 million.分析記事 • Aug 10
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Surges 25% Yet Its Low P/S Is No Reason For Excitement
NasdaqGM:ANIP 1 Year Share Price vs Fair Value Explore ANI Pharmaceuticals's Fair Values from the Community and select...分析記事 • Jun 21
Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • May 16
We Think Shareholders Will Probably Be Generous With ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) CEO Compensation
Key Insights ANI Pharmaceuticals' Annual General Meeting to take place on 22nd of May Total pay for CEO Nikhil Lalwani...分析記事 • Mar 28
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Fly 25% But Investors Aren't Buying For Growth
ANI Pharmaceuticals, Inc. ( NASDAQ:ANIP ) shareholders have had their patience rewarded with a 25% share price jump in...分析記事 • Feb 25
Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Feb 11
ANI Pharmaceuticals: More Than Just A Generics Company
Summary ANI Pharmaceuticals offers an asymmetric opportunity in small-cap pharma, with a niche in generics, rare disease treatments, and contract manufacturing. Despite cash burn concerns, ANI's revenue growth, strategic moves, and overlooked royalty streams indicate long-term value creation. ANI's rare disease asset, Purified Cortrophin Gel, and generics pipeline, including Prucalopride, position it for significant revenue growth and market re-rating. The company's debt restructuring and diversified revenue streams enhance financial stability, making it a potential buyout target in the specialty pharma sector. Read the full article on Seeking Alpha分析記事 • Dec 18
ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Prospects Need A Boost To Lift Shares
You may think that with a price-to-sales (or "P/S") ratio of 2x ANI Pharmaceuticals, Inc. ( NASDAQ:ANIP ) is a stock...分析記事 • Nov 09
Here's Why ANI Pharmaceuticals (NASDAQ:ANIP) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Seeking Alpha • Nov 02
ANI Pharmaceuticals Is Acting Like It Is Being Acquired
Summary Several actions or omissions by ANIP is consistent with them being acquired and being restricted in what they can disclose. Offer could exceed $8 billion plus sales based CVRs. Offer likely contingent on FDA approval of NDA filed in Q3 2023 for undisclosed drug filed by ANIP but application appears to be financed by undisclosed partner. Read the full article on Seeking AlphaSeeking Alpha • Oct 11
ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market
Summary Today, we revisit small biopharma ANI Pharmaceuticals, as it is a GARP stock trading near technical support, with solid growth prospects. The company recently acquired Alimera Sciences for $380 million, boosting its rare disease segment with a couple of durable ophthalmology products. Analyst firms are generally bullish on the company's prospects and the stock trades at 12 times trailing earnings, despite revenue growth in the high teens. An analysis of ANIP follows in the paragraphs below. Read the full article on Seeking Alpha
新しいナラティブ • Sep 15
Purified Cortrophin Gel And Strategic Acquisitions Propel Robust Revenue Surge In Rare Disease Sector
Accelerating demand for their lead Rare Disease asset and growth in generics, along with expanding sales efforts, are expected to significantly boost revenues.分析記事 • Sep 10
There's No Escaping ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Muted Revenues
ANI Pharmaceuticals, Inc.'s ( NASDAQ:ANIP ) price-to-sales (or "P/S") ratio of 2.2x might make it look like a buy right...分析記事 • Aug 14
ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem
ANI Pharmaceuticals, Inc.'s ( NASDAQ:ANIP ) robust earnings report didn't manage to move the market for its stock. Our...分析記事 • Aug 08
Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Aug 02
ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028
Summary ANIP has three 505(b)(2) NDA submissions under FDA review, including oral liquid terazosin, female testosterone drug, and oral liquid hydrochlorothiazide. Potential peak sales for Tezruly and hydrochlorothiazide in the US could exceed $500 million, while the female testosterone drug could generate $290 million in royalties. ANIP's revenue could reach $1.41 billion in sales and $290 million in royalties by 2028, with significant growth potential. Read the full article on Seeking Alpha分析記事 • Jun 10
Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price
There wouldn't be many who think ANI Pharmaceuticals, Inc.'s ( NASDAQ:ANIP ) price-to-sales (or "P/S") ratio of 2.5x is...Seeking Alpha • Jun 10
ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked
Summary ANIP's potential royalty revenue from two upcoming drug applications could generate $415 million annually, not reflected in the current share price. ANI Pharmaceuticals' legal action against CG Oncology could result in royalties for Cretostimogene, potentially adding $125 million per year. The Company's female testosterone drug could generate royalties of $290 million per year, with potential for additional indications and international sales. Read the full article on Seeking Alpha株主還元
| ANIP | US Pharmaceuticals | US 市場 | |
|---|---|---|---|
| 7D | 1.8% | 1.4% | 1.6% |
| 1Y | 31.8% | 48.6% | 18.6% |
業界別リターン: ANIP過去 1 年間で48.6 % の収益を上げたUS Pharmaceuticals業界を下回りました。
リターン対市場: ANIP過去 1 年間で18.6 % の収益を上げたUS市場を上回りました。
価格変動
| ANIP volatility | |
|---|---|
| ANIP Average Weekly Movement | 4.4% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: ANIP 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: ANIPの 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2001 | 970 | Nikhil Lalwani | www.anipharmaceuticals.com |
バイオ医薬品会社であるANI Pharmaceuticals, Inc.は、米国内外でブランドおよびジェネリック医薬品の開発、製造、販売を行っている。同社は、注射剤、ソフトジェルカプセル、コルトロフィンゲル、ILUVIENおよびYUTIQ製品を提供している。また、経口固形製剤、半固形製剤、液剤、外用剤、規制薬物、強力製剤も製造している。同社は全国規模の卸売業者、専門薬局、小売薬局チェーン、流通業者、通信販売業者、グループ購買組織、病院や医療提供者に製品を提供している。ANI Pharmaceuticals, Inc.は2001年に法人化され、ミネソタ州ボーデットに本社を置いている。
ANI Pharmaceuticals, Inc. 基礎のまとめ
| ANIP 基礎統計学 | |
|---|---|
| 時価総額 | US$1.82b |
| 収益（TTM） | US$83.94m |
| 売上高(TTM) | US$923.71m |
21.7x
PER（株価収益率2.0x
P/SレシオANIP は割高か？
公正価値と評価分析を参照収益と収入
| ANIP 損益計算書（TTM） | |
|---|---|
| 収益 | US$923.71m |
| 売上原価 | US$361.86m |
| 売上総利益 | US$561.85m |
| その他の費用 | US$477.92m |
| 収益 | US$83.94m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 3.96 |
| グロス・マージン | 60.83% |
| 純利益率 | 9.09% |
| 有利子負債／自己資本比率 | 109.2% |
ANIP の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/05 22:41 |
| 終値 | 2026/07/02 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
ANI Pharmaceuticals, Inc. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16
| アナリスト | 機関 |
|---|---|
| Glen Santangelo | Barclays |
| Dewey Steadman | Canaccord Genuity |
| Timothy Chiang | Capital One Securities, Inc. |